These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 31387920)

  • 41. Injecting Hope--A Review of Breast Cancer Vaccines.
    Mittendorf EA; Peoples GE
    Oncology (Williston Park); 2016 May; 30(5):475-81, 485. PubMed ID: 27188680
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Personalized Immuno-Oncology.
    Jain KK
    Med Princ Pract; 2021; 30(1):1-16. PubMed ID: 32841942
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Targeting the immune system in cancer.
    Chaudhuri D; Suriano R; Mittelman A; Tiwari RK
    Curr Pharm Biotechnol; 2009 Feb; 10(2):166-84. PubMed ID: 19199949
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Intratumoral CpG-B Promotes Antitumoral Neutrophil, cDC, and T-cell Cooperation without Reprograming Tolerogenic pDC.
    Humbert M; Guery L; Brighouse D; Lemeille S; Hugues S
    Cancer Res; 2018 Jun; 78(12):3280-3292. PubMed ID: 29588348
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hijacked Immune Cells in the Tumor Microenvironment: Molecular Mechanisms of Immunosuppression and Cues to Improve T Cell-Based Immunotherapy of Solid Tumors.
    Balta E; Wabnitz GH; Samstag Y
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072260
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy.
    Farsaci B; Higgins JP; Hodge JW
    Int J Cancer; 2012 Apr; 130(8):1948-59. PubMed ID: 21633954
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Genomic Characterization of Six Virus-Associated Cancers Identifies Changes in the Tumor Immune Microenvironment and Altered Genetic Programs.
    Varn FS; Schaafsma E; Wang Y; Cheng C
    Cancer Res; 2018 Nov; 78(22):6413-6423. PubMed ID: 30254145
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tissue-resident memory CD8
    Wang T; Shen Y; Luyten S; Yang Y; Jiang X
    Pharmacol Res; 2020 Sep; 159():104876. PubMed ID: 32422340
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Old-School Chemotherapy in Immunotherapeutic Combination in Cancer, A Low-cost Drug Repurposed.
    Abu Eid R; Razavi GS; Mkrtichyan M; Janik J; Khleif SN
    Cancer Immunol Res; 2016 May; 4(5):377-82. PubMed ID: 27196429
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Therapeutic cancer vaccines: From initial findings to prospects.
    Song Q; Zhang CD; Wu XH
    Immunol Lett; 2018 Apr; 196():11-21. PubMed ID: 29407608
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Combining vaccines and immune checkpoint inhibitors to prime, expand, and facilitate effective tumor immunotherapy.
    Collins JM; Redman JM; Gulley JL
    Expert Rev Vaccines; 2018 Aug; 17(8):697-705. PubMed ID: 30058393
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunomodulation of the Tumor Microenvironment: Turn Foe Into Friend.
    Locy H; de Mey S; de Mey W; De Ridder M; Thielemans K; Maenhout SK
    Front Immunol; 2018; 9():2909. PubMed ID: 30619273
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Computational Characterization of Suppressive Immune Microenvironments in Glioblastoma.
    Luoto S; Hermelo I; Vuorinen EM; Hannus P; Kesseli J; Nykter M; Granberg KJ
    Cancer Res; 2018 Oct; 78(19):5574-5585. PubMed ID: 29921698
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Adverse Events in Cancer Immunotherapy.
    Abdel-Wahab N; Alshawa A; Suarez-Almazor ME
    Adv Exp Med Biol; 2017; 995():155-174. PubMed ID: 28321817
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antibody-Drug Conjugates Bearing Pyrrolobenzodiazepine or Tubulysin Payloads Are Immunomodulatory and Synergize with Multiple Immunotherapies.
    Rios-Doria J; Harper J; Rothstein R; Wetzel L; Chesebrough J; Marrero A; Chen C; Strout P; Mulgrew K; McGlinchey K; Fleming R; Bezabeh B; Meekin J; Stewart D; Kennedy M; Martin P; Buchanan A; Dimasi N; Michelotti E; Hollingsworth R
    Cancer Res; 2017 May; 77(10):2686-2698. PubMed ID: 28283653
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Chemotherapy and tumor immunity: an unexpected collaboration.
    Emens LA
    Front Biosci; 2008 Jan; 13():249-57. PubMed ID: 17981543
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Paclitaxel Reduces Tumor Growth by Reprogramming Tumor-Associated Macrophages to an M1 Profile in a TLR4-Dependent Manner.
    Wanderley CW; Colón DF; Luiz JPM; Oliveira FF; Viacava PR; Leite CA; Pereira JA; Silva CM; Silva CR; Silva RL; Speck-Hernandez CA; Mota JM; Alves-Filho JC; Lima-Junior RC; Cunha TM; Cunha FQ
    Cancer Res; 2018 Oct; 78(20):5891-5900. PubMed ID: 30104241
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Searching for Goldilocks: How Evolution and Ecology Can Help Uncover More Effective Patient-Specific Chemotherapies.
    Park DS; Luddy KA; Robertson-Tessi M; O'Farrelly C; Gatenby RA; Anderson ARA
    Cancer Res; 2020 Dec; 80(23):5147-5154. PubMed ID: 32934022
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Conference scene: immune effector mechanisms in tumor immunity.
    Sikora AG; Hailemichael Y; Overwijk WW
    Immunotherapy; 2012 Feb; 4(2):141-3. PubMed ID: 22339456
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunomodulation in cancer.
    Hegmans JP; Aerts JG
    Curr Opin Pharmacol; 2014 Aug; 17():17-21. PubMed ID: 25011112
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.